Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rigel Pharmaceuticals, Inc. - Common Stock (NQ:RIGL)

30.05 +0.66 (+2.25%)
Streaming Delayed Price Updated: 3:02 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rigel Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines Strong Growth and Bullish Technicals
RIGL stock shows strong revenue & earnings growth with a low P/E ratio. Its technical chart pattern suggests a potential breakout from a recent trading range. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Embodies the 'Affordable Growth' Investment Strategy
Rigel Pharmaceuticals offers strong growth and earnings at an affordable valuation, making it a compelling candidate for the "Affordable Growth" investment strategy. 
Via Chartmill
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Stands Out as a Top Growth Stock Candidate
RIGL stock shows explosive growth with 5,567% EPS surge, soaring sales, and strong earnings surprises, fitting a proven growth investing model. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL): An Affordable Growth Stock with Strong Upside Potential
Rigel Pharmaceuticals (RIGL) offers high growth with a low P/E ratio. Strong EPS & revenue growth meet an affordable valuation, fitting the "affordable growth" investment profile. 
Via Chartmill
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
A Preview Of Rigel Pharmaceuticals's Earnings
 
Via Benzinga
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Identified as a Top Value Stock with Strong Fundamentals
Rigel Pharmaceuticals (RIGL) is a biotech stock with a compelling valuation, trading at a low P/E ratio. It boasts strong profitability, exceptional revenue & EPS growth, and solid financial health. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Explosive Growth, Fits Navellier's 'Little Book' Strategy
Rigel Pharmaceuticals shows explosive growth with 729% EPS growth, 106% revenue surge, and a 119% ROE, making it a top pick for momentum investors. 
Via Chartmill
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines High Growth Momentum with Strong Technical Setup
Discover RIGL stock's high growth momentum & strong technical setup. A top pick for investors seeking earnings acceleration & breakout potential. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Affordable Growth Stock
Rigel Pharmaceuticals (RIGL) is a GARP stock with explosive 729% EPS growth, trading at a deep discount with a P/E of just 7.11. 
Via Chartmill
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A Deep Value Stock with Strong Fundamentals
Rigel Pharmaceuticals (RIGL) presents a strong value investing case with a high valuation score, robust profitability, and impressive revenue growth, trading below intrinsic value. 
Via Chartmill
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Growth Stock on Navellier's Screening Model
Rigel Pharmaceuticals (RIGL) excels in a proven growth stock screening method, showing massive earnings growth, soaring revenue, and a high return on equity. 
Via Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
Unusual volume stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
Rigel (RIGL) Q2 Revenue Jumps 176%
Via The Motley Fool
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Aligns Perfectly with Louis Navellier’s Growth Investing Strategy
Louis Navellier’s growth investing strategy highlights stocks like RIGL with strong earnings momentum, rising sales, and profitability, making it a standout pick for investors. 
Via Chartmill
What to Expect from Rigel Pharmaceuticals's Earnings
 
Via Benzinga
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday?
The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points.  
Via Benzinga
Topics Government Stocks
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?
U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions. 
Via Benzinga
Topics World Trade
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam. 
Via Stocktwits
Earnings Scheduled For March 4, 2025
 
Via Benzinga
Dow Jumps Over 200 Points, Crude Oil Gains 1.5%
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.